Antibodies neutralising GnRH have the potential to act as androgen-deprivation therapy used to date to treat prostate cancer [29]–[31], since prostate cancer cells depend on testosterone for growth [32]. This evidence concerns the gene GNRH1 and prostate carcinoma.